AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selec ...

Vensana Capital—an independent, medtech-focused venture capital investment firm supported by Versant Ventures—has launched with a $225 million fund and ambitions to support new breakthroughs ...

Iron Path Capital has made an investment in Versant Diagnostics, a physician services company focused on anatomic pathology.

Repare Therapeutics has raised an $82.5 million series B round to take synthetic lethality drugs into humans. The Versant Ventures-founded biotech plans to start testing ATR inhibitor RP-3500 in ...

Versant Ventures today announced the acquisition of portfolio company BlueRock Therapeutics by Bayer AG for up to $1 billion in total value. For the f ...